REMODEL T1D

Read more in:

Do you have Type 1 Diabetes and Diabetic Kidney Disease?

Kidney disease is common in type 1 diabetes (T1D). Diabetic kidney disease can cause many problems, such as kidney failure that needs dialysis or kidney transplantation, or damage to the heart and blood vessels that can lead to heart failure or stroke. That’s why treatments that prevent and treat kidney disease in T1D are very important.

The University of Washington (UW) is looking for participants for the REMODEL T1D study. The purpose of this study is to test whether semaglutide (commonly known as Ozempic) protects the kidneys in those with T1D. Semaglutide has been shown to reduce blood glucose and body weight and protect the kidneys in type 2 diabetes. It is possible that semaglutide has similar benefits in T1D, but this is not known. Because of this, the use of semaglutide in those with T1D, such as in this study, is experimental. The study will be conducted at the UW South Lake Union Diabetes Institute in Seattle.

You may be eligible to join this study if:

  • You are 18 years or older
  • You have had Type 1 Diabetes greater than or equal to 5 years
  • You have protein (albumin) in the urine
  • Your A1C is less than 9%

Procedures involved include:

  • Blood draw
  • Urine sample
  • MRI
  • Eye Exam
  • Once weekly injections of semaglutide

If interested, please contact the REMODEL T1D Research Coordinators at UW: